Clinical Trial: A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes

Brief Summary: A study of ASP2151 in subjects with recurrent outbreaks of genital herpes.

Detailed Summary:
Sponsor: Astellas Pharma Inc

Current Primary Outcome: To compare the efficacy and safety of ASP2151 with valacyclovir and placebo in the acute treatment of recurrent genital Herpes Simplex Virus Infection [ Time Frame: 17 days ]

Original Primary Outcome: To compare the efficacy and safety of ASP2151 with valacyclovir and placebo in the acute treatment of recurrent genital Herpes Simplex Virus Infection

Current Secondary Outcome: Pharmacokinetics in study patients [ Time Frame: 4 days ]

Original Secondary Outcome: Pharmacokinetics in study patients

Information By: Astellas Pharma Inc

Dates:
Date Received: June 12, 2007
Date Started: June 2007
Date Completion:
Last Updated: February 27, 2013
Last Verified: February 2013